← Back to Screener
Kailera Therapeutics, Inc. Common Stock (KLRA)
Price$23.18
Momentum ScoreA
Favorite Metrics
Price vs S&P 500 (4W)-13.76%
VGM Score81.31
All Metrics
Indicated Dividend (Annual)$0.00
Price vs S&P 500 (YTD)-18.29%
10-Day Avg Trading Volume0.43M
3-Month Avg Trading Volume0.93M
52-Week High$28.23
Year-to-Date Return-11.77%
5-Day Price Return8.36%
Month-to-Date Return-8.24%
Beta-3.03x
52-Week Low$19.01
mGradeA
vgmGradeA
Show chart for
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
KLRAKailera Therapeutics, Inc. Common Stock | — | — | A | $23.18 |
| LLYEli Lilly & Co. | D | B | B | $1082.20 |
| JNJJohnson & Johnson | C | C | C | $223.51 |
| ABBVABBVIE INC. | D | C | C | $212.93 |
| MRKMerck & Co., Inc. | C | C | C | $115.17 |
| NVSNovartis AG | C | C | C | $145.68 |
| AZNAstraZeneca PLC | D | B | C | $179.71 |
| NVONovo-Nordisk A/S | B | B | C | $44.07 |
| PFEPfizer Inc. | B | C | C | $25.63 |
| ABTAbbott Laboratories | C | C | D | $87.78 |
| TEVATeva Pharmaceutical Industries Limited American Depositary Shares | C | C | C | $34.64 |
About
Kailera Therapeutics Inc is a clinical-stage biotechnology company. The company focuses on developing a diversified pipeline to provide options for people living with obesity. The company is progressing four clinical-stage product candidates, leveraging multiple GLP-1 based mechanisms of action and routes of administration. The company's obesity-first approach seeks to advance product candidates with the potential to maximize weight loss and address critical needs in the current therapeutic landscape.